EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.

EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.
复制标题

DOI:
10.1038/nrclinonc.2017.44
复制
发表时间:
2017-10
期刊:
Nature reviews. Clinical oncology
影响因子:
--
通讯作者:
Weinberg RA
Weinberg RA
中科院分区:
其他
文献类型:
--
作者:
Shibue T;Weinberg RA

文献摘要

参考文献

被引文献

相似文献

抗癌治疗的成功通常受到耐药性发展的限制。这种获得性耐药性部分是由肿瘤内异质性驱动的,即共同居住在单个肿瘤块中的癌细胞的表型多样性。癌症干细胞(CSC)概念的引入,假定存在少数能够接种新肿瘤的CSC亚群,为理解肿瘤内异质性的一个维度提供了一个框架。这一概念,结合上皮-间充质转化(EMT)程序作为CSC表型的关键调节因子的鉴定,提供了一个研究肿瘤内异质性的性质和抗癌药物耐药性的可能机制基础的机会。事实上,越来越多的证据表明,常规疗法通常无法根除通过激活EMT程序进入CSC状态的癌细胞,从而允许CSC介导的临床复发。在这篇综述中,我们总结了我们目前对EMT计划和CSC状态之间联系的理解,并讨论了这些知识如何有助于改善临床实践。
The success of anticancer therapy is usually limited by the development of drug resistance. Such acquired resistance is driven, in part, by intratumoural heterogeneity — that is, the phenotypic diversity of cancer cells co-inhabiting a single tumour mass. The introduction of the cancer stem cell (CSC) concept, which posits the presence of minor subpopulations of CSCs that are uniquely capable of seeding new tumours, has provided a framework for understanding one dimension of intratumoural heterogeneity. This concept, taken together with the identification of the epithelial-to-mesenchymal transition (EMT) programme as a critical regulator of the CSC phenotype, offers an opportunity to investigate the nature of intratumoural heterogeneity and a possible mechanistic basis for anticancer drug resistance. In fact, accumulating evidence indicates that conventional therapies often fail to eradicate carcinoma cells that have entered the CSC state via activation of the EMT programme, thereby permitting CSC-mediated clinical relapse. In this Review, we summarize our current understanding of the link between the EMT programme and the CSC state, and also discuss how this knowledge can contribute to improvements in clinical practice.
DOI: 10.1158/0008-5472.can-07-6849
发表时间: 2008-08-01
期刊: Cancer research
影响因子: 11.2
作者:
Barkan D;Kleinman H;Simmons JL;Asmussen H;Kamaraju AK;Hoenorhoff MJ;Liu ZY;Costes SV;Cho EH;Lockett S;Khanna C;Chambers AF;Green JE
通讯作者: Green JE
DOI: 10.1128/mcb.21.23.8184-8188.2001
发表时间: 2001-12-01
影响因子: 5.3
作者:
Carver, EA;Jiang, RL;Gridley, T
通讯作者: Gridley, T
DOI: 10.1038/mt.2013.116
发表时间: 2013-08-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Boisgerault, Nicolas;Kottke, Timothy;Vile, Richard
通讯作者: Vile, Richard
DOI: 10.1038/nrc1740
发表时间: 2005-11-01
影响因子: 78.5
作者:
Bjerkvig, R;Tysnes, BB;Terzis, AJA
通讯作者: Terzis, AJA
DOI: 10.1016/0092-8674(94)90077-9
发表时间: 1994-12-02
期刊: CELL
影响因子: 64.5
作者:
BAIN, G;MAANDAG, ECR;MURRE, C
通讯作者: MURRE, C